The institutional cluster is a strong bullish signal, but the 45-day reporting lag means positions were set at June 30 prices. Monitor for any insider open-market buying (Form 4) to confirm conviction, and watch for Phase 2 MOMENTUM enrollment completion (expected Q1 2027) as the next catalyst. The $300.4M cash runway removes near-term dilution risk.
Executive Summary
Eight major institutional investors, including BlackRock, State Street, and Fidelity, more than doubled their C4 Therapeutics positions in Q2 2026, adding a net $72.1M to bring aggregate holdings to $90.9M. The cluster follows a Q2 earnings beat (EPS -$0.18 vs -$0.23 consensus) and a $300.4M cash runway extending to end 2028, suggesting institutions are positioning ahead of Phase 2 MOMENTUM data expected in 2H 2027. The signal is strong but tempered by the 45-day 13F reporting lag and absence of corroborating insider open-market buying.
Key Financial Metrics
Institutional Positions
Net institutional flow: $72.0M
▲ Buyers (8)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| BlackRock | DOUBLED | +285.5% | $36.9M | $31.5M |
| JPMorgan | ADD | +47.3% | $20.7M | $13.1M |
| State Street | DOUBLED | +452.4% | $9.9M | $8.9M |
| Geode | DOUBLED | +165.2% | $11.8M | $9.3M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Walleye Capital | TRIM | -51.9% | $629.0K | -$91.2K |
Key Facts
- 8 institutions accumulated $72.1M net in Q2 2026, bringing total holdings to $90.9M
- BlackRock doubled to 7.90M shares ($36.9M), the largest position
- State Street quintupled to 2.12M shares ($9.9M), the largest % increase at +452%
- Only 1 seller (Walleye Capital trimmed -$91K), negligible selling pressure
- Q2 2026 revenue $6.6M (+2.7% YoY), EPS beat consensus by 21.7%
- Cash $300.4M extends runway to end 2028, funding Phase 2 MOMENTUM through data readout
- No insider open-market buying in the window — institutions-only signal
Financial Impact
8 institutions accumulated $72.1M in new positions while 1 reduced holdings by $91K — net institutional inflow of ~$72.0M
Risk Factors
- 45-day 13F reporting lag — positions may have been unwound since quarter-end
- No insider open-market buying to corroborate institutional conviction
- Pre-revenue biotech with binary Phase 2 data risk in 2H 2027
- Cluster dominated by mega-passive managers (BlackRock, State Street, Geode, Fidelity) — may reflect index rebalancing, not active conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CCCC-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 144 | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | — |
Aug 14, 2026 6w ago | Institutional Cluster | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | — |
Aug 11, 2026 7w ago | 8-K | $3.62 $4.18 | ▲ +15.47% | ▲ +15.87% | — |
Jun 11, 2026 16w ago | Press Release | $3.87 $3.92 | ▲ +1.29% | ▲ +0.86% | — |
May 15, 2026 19w ago | 8-K | $3.22 $3.49 | ▲ +8.39% | ▲ +6.77% | — |
May 12, 2026 20w ago | 8-K | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | — |
May 12, 2026 20w ago | Press Release | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | — |
Apr 9, 2026 25w ago | 8-K | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | — |
Apr 9, 2026 25w ago | Press Release | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | — |
Mar 25, 2026 27w ago | Press Release | $2.69 $2.70 | ▲ +0.37% | ▲ +0.62% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access